BR112021023485A2 - Anticorpos anti-vírus da hepatite b e uso dos mesmos - Google Patents

Anticorpos anti-vírus da hepatite b e uso dos mesmos

Info

Publication number
BR112021023485A2
BR112021023485A2 BR112021023485A BR112021023485A BR112021023485A2 BR 112021023485 A2 BR112021023485 A2 BR 112021023485A2 BR 112021023485 A BR112021023485 A BR 112021023485A BR 112021023485 A BR112021023485 A BR 112021023485A BR 112021023485 A2 BR112021023485 A2 BR 112021023485A2
Authority
BR
Brazil
Prior art keywords
hbv
antibodies
hepatitis
hbsag
subject
Prior art date
Application number
BR112021023485A
Other languages
English (en)
Inventor
Chao Yu
Jixian Tang
Ningshao Xia
Quan Yuan
Tianying Zhang
Wenxin Luo
Xiaoqing Chen
Yichao Jiang
Original Assignee
Univ Xiamen
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Xiamen, Yang Sheng Tang Co Ltd filed Critical Univ Xiamen
Publication of BR112021023485A2 publication Critical patent/BR112021023485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)

Abstract

anticorpos anti-vírus da hepatite b e uso dos mesmos. anticorpos (especialmente anticorpos humanizados) contra o antígeno de superfície da hepatite b (hbsag), uma molécula de ácido nucleico que codifica o mesmo, um método para prepará-los e uma composição farmacêutica contendo os mesmos. os anticorpos anti-hbsag têm uma afinidade de ligação mais alta ao hbsag em um ph neutro do que em um ph ácido, aumentando significativamente a eficiência de eliminação do vírus e prolongando o tempo de inibição do vírus. os anticorpos e a composição farmacêutica podem ser usados para prevenir e / ou tratar infecções por hbv ou doenças relacionadas à infecção por hbv (como hepatite b) para uso na neutralização da virulência de hbv no corpo de um sujeito (como um ser humano) para reduzir um nível sérico de hbv dna e / ou hbsag no corpo do sujeito, ou para ativar uma resposta imune humoral de um sujeito (como uma pessoa infectada com hbv crônico ou um paciente com hepatite b crônica) contra o hbv.
BR112021023485A 2019-05-23 2020-05-22 Anticorpos anti-vírus da hepatite b e uso dos mesmos BR112021023485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910432602 2019-05-23
PCT/CN2020/091890 WO2020233715A1 (zh) 2019-05-23 2020-05-22 抗乙肝病毒抗体及其用途

Publications (1)

Publication Number Publication Date
BR112021023485A2 true BR112021023485A2 (pt) 2022-02-08

Family

ID=73441881

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021023483A BR112021023483A2 (pt) 2019-05-23 2020-05-22 Novo anticorpo anti-vírus da hepatite b e seus usos
BR112021023485A BR112021023485A2 (pt) 2019-05-23 2020-05-22 Anticorpos anti-vírus da hepatite b e uso dos mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021023483A BR112021023483A2 (pt) 2019-05-23 2020-05-22 Novo anticorpo anti-vírus da hepatite b e seus usos

Country Status (9)

Country Link
US (2) US20220251173A1 (pt)
EP (2) EP3974446A4 (pt)
JP (2) JP2022534080A (pt)
KR (2) KR20220012338A (pt)
CN (1) CN111978393A (pt)
AU (2) AU2020280539A1 (pt)
BR (2) BR112021023483A2 (pt)
CA (2) CA3141673A1 (pt)
WO (2) WO2020233715A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2000253878A (ja) * 1999-03-09 2000-09-19 Nisshinbo Ind Inc ヒト抗ＨＢｓ抗体
CN102056946A (zh) * 2008-04-11 2011-05-11 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
NZ595993A (en) * 2009-03-31 2013-05-31 Oridis Biomarkers Gmbh Method for diagnosis of cancer and monitoring of cancer treatments
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA2850322C (en) * 2011-09-30 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
EP2860188B1 (en) * 2012-06-11 2020-10-21 Xiamen University Polypeptides and antibodies for treating hbv infection and related diseases
EP3225628A4 (en) * 2014-11-28 2018-03-14 Celltrion Inc. Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus
WO2017032303A1 (zh) * 2015-08-25 2017-03-02 厦门大学 一种用于展示目的多肽的多肽载体及其用途
CN106565840B (zh) * 2015-10-09 2020-09-01 厦门大学 抗乙肝表面抗原的抗体及其用途
US11324819B2 (en) * 2016-04-06 2022-05-10 University Of Washington Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
CA3032820A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
US10987418B2 (en) * 2017-02-17 2021-04-27 Xiamen University Polypeptide carrier for presenting target polypeptide and uses thereof
CN113480641B (zh) * 2017-04-07 2023-04-11 厦门大学 用于治疗乙肝感染及相关疾病的抗体
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies

Also Published As

Publication number Publication date
EP3974446A1 (en) 2022-03-30
EP3981786A1 (en) 2022-04-13
US20220251173A1 (en) 2022-08-11
BR112021023483A2 (pt) 2022-02-08
CN111978393A (zh) 2020-11-24
JP2022534080A (ja) 2022-07-27
JP7372638B2 (ja) 2023-11-01
AU2020280539A1 (en) 2022-01-27
EP3974446A4 (en) 2023-08-02
EP3981786A4 (en) 2023-07-26
KR20220012297A (ko) 2022-02-03
KR20220012338A (ko) 2022-02-03
AU2020280543A1 (en) 2022-01-27
CA3141673A1 (en) 2020-11-26
CA3141648A1 (en) 2020-11-26
US20220235117A1 (en) 2022-07-28
WO2020233715A1 (zh) 2020-11-26
JP2022542743A (ja) 2022-10-07
WO2020233695A1 (zh) 2020-11-26
CN111978392A (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
JPH085804B2 (ja) Ａ型及びｂ型肝炎混合アジュバントワクチン
Lampertico et al. Add‐on peginterferon alfa‐2a to nucleos (t) ide analogue therapy for Caucasian patients with hepatitis B ‘e’antigen‐negative chronic hepatitis B genotype D
JP2016505589A5 (pt)
Brzoska et al. Interferons in the therapy of severe coronavirus infections: a critical analysis and recollection of a forgotten therapeutic regimen with interferon beta
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
RU2010126598A (ru) Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в
BR112018007121A2 (pt) anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv
Yoshida et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study
RU2008151516A (ru) СПОСОБ УВЕЛИЧЕНИЯ БИОЛОГИЧЕСКОЙ АКТИВНОСТИ ОЧИЩЕННОГО БЕЛКА HspE7
Fujibayashi et al. Production of interferon by immune lymphocytes exposed to herpes simplex virus-antibody complexes
BR112021023485A2 (pt) Anticorpos anti-vírus da hepatite b e uso dos mesmos
Lelie et al. Immune Response to a Heat-Inactivated Hepatitis B Vaccine in Patients Undergoing Hemodialysis: Enhancement of the Response by Increasing the Dose of Hepatitis B Surface Antigen From 3 to 27 µg
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
Howard et al. Preparation and properties of immune-stimulating complexes containing hepatitis B virus surface antigen
EP0188499A1 (en) An antiviral preparation and the method of its production
Antonelli et al. Clinical significance of recombinant interferon-α2 neutralizing antibodies in hepatitis patients
van Campenhout et al. How to achieve immune control in chronic hepatitis B?
Polychronopoulou-Androulakaki et al. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine
CN102241744B (zh) 一种病毒感染阻断剂、其药物组合物及其应用
BR112022010425A2 (pt) Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
Saab et al. Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients
McLeod et al. Effect of cortisone on latent syphilis in rabbits and mice
Alexander et al. A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection: a preliminary analysis of the first 32 patients
Elezi et al. INCIDENCE AND PREVALENCE OF HEPATITIS A AND B IN THE REGION OF GOSTIVAR FOR THE PERIOD 2010-2015.
Kar et al. Hepatitis B Vaccination Amongst Medical Students: Is There a Need to Review Seroconversion Post Vaccination?